You can watch OTLKW and buy or sell other stocks, options, and ETFs commission-free!
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ. The listed name for OTLKW is Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022.
Lawrence A. Kenyon, CPA
South Brunswick, New Jersey
52 Week High
52 Week Low